The impact of crystallization conditions on structure-based drug design: A case study on the methylene blue/acetylcholinesterase complex
The impact of crystallization conditions on structure-based drug design: A case study on the methylene blue/acetylcholinesterase complex
复制标题
DOI：
10.1002/pro.2923
复制
发表时间：
2016-06-01
期刊：
影响因子：
8
通讯作者：
Silman, Israel
中科院分区：
文献类型：
--
作者：
Dym, Orly;Song, Wanling;Silman, Israel
基于结构的药物设计利用从PDB检索到的载脂蛋白或复杂结构。57%的结晶学PDB条目是使用聚乙二醇类(PEGS)作为沉淀剂和/或作为冷冻保护剂获得的，但是
Structure-based drug design utilizes apoprotein or complex structures retrieved from the PDB. >57% of crystallographic PDB entries were obtained with polyethylene glycols (PEGs) as precipitant and/or as cryoprotectant, but